Dr. Matthew Galsky interprets latest atezolizumab/chemo results in bladder cancer

April 16, 2021
Urology Times staff

Matthew D. Galsky, MD, interprets the results from the final overall survival (OS) analysis of the IMvigor130 trial, which were shared during the 2021 American Association for Cancer Research Virtual Annual Meeting. The IMvigor130 trial randomized patients with metastatic urothelial carcinoma to atezolizumab plus platinum/gemcitabine; atezolizumab alone; or placebo plus platinum/gemcitabine.

Galsky says that the final OS analysis comparing atezolizumab/chemo versus placebo/chemo did not show a statistically significant OS benefit with atezolizumab, and thus, OS follow-up remains ongoing. Galsky also discusses the finding from an exploratory analysis which suggest that outcomes with atezolizumab/chemo might be affected by the specific platinum regimen used.

Galsky is professor of Medicine; director of Genitourinary Medical Oncology; director of the Novel Therapeutics Unit; and co-director of the Center of Excellence for Bladder Cancer at the Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai.